Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for ta393

  1. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  2. Implementation of NICE TA393/394 in a tertiary Lipid Clinic - the first three years experience

    hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Shared learning
    Published
    7 October 2019

  3. Innovative Medicines Optimisation Clinic for PCSK9 inhibitors & Statin Intolerance

    meet target LDL-C levels. The NICE published technology appraisal guidance TA393 and 394 provided a new opportunity and hope for those...

    Shared learning
    Last updated
    27 September 2019

  4. New opportunities for the treatment of hyperlipidaemia: Initiation of PCSK9 monoclonal antibodies utilising a multi-disciplinary approach.

    Therefore, NICE approval of PCSK9 monoclonal antibodies in the form of TA393 & TA394 (June 2016), offered an additional treatment...

    Shared learning
    Published
    21 March 2019

  5. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA393